Press releases

STOCKHOLM — June 30, 2020 — Oncopeptides AB (publ) (“Oncopeptides”) (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob Lindberg who has been CEO since the restart of the company in 2011. Jakob Lindberg assumes the role as Chief Scientific Officer, CSO, replacing MD Christian Jacques who has held the position as CSO since 2018. Christian will continue as a Senior Advisor.

Stockholm — June 30, 2020 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of exercise of warrants under the company’s incentive programs

STOCKHOLM — June 30, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the Company submits a New Drug Application (NDA) to the U.S. Food and Drug Administration, FDA, for accelerated approval of melflufen (INN melphalan flufenamide) in combination with dexamethasone for the treatment of adult patients with multiple myeloma whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent and one anti-CD38 monoclonal antibody (i.e., triple-class refractory multiple myeloma patients)

STOCKHOLM — June 29, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that the Company has agreed with Kancera to take over Kancera’s drug development facility in Solna, Sweden. The agreement is an important step in the development of Oncopeptides’ pre-clinical operations and marks an additional reinforcement of the Company´s research capacity. Oncopeptides recruits several employees with pre-clinical expertise from Kancera and takes over the lease contract for laboratory facilities as well as equipment

STOCKHOLM — June 15, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that the full top-line results from the pivotal phase 2 HORIZON study, evaluating intravenous melflufen in combination with dexamethasone in patients with relapsed refractory multiple myeloma (RRMM), have been presented at the ongoing 25[th] European Hematology Association meeting, EHA. The results support the NDA submission to the US Food and Drug Administration, FDA, for accelerated approval of melflufen. The Company is on track to submit the application to FDA by the end of Q2, 2020

STOCKHOLM — June 11, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that the Company hosts a symposium at the EHA 25 Virtual Edition on June 13[th], focusing on the “Challenges in Managing Patients with Myeloma”. A panel of international experts will discuss disease assessment and treatment options in myeloma and share clinical experiences of managing patients that are difficult to treat

STOCKHOLM — June 1, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announces that patients in the OCEAN study stay on treatment longer than previously estimated. As a consequence, top-line results are estimated for H1 2021 instead of previously communicated Q4 2020. Patient recruitment in OCEAN will remain open to ensure that the 339 disease progression events needed to complete the study can be reached within a reasonable timeframe

Stockholm —May 29, 2020 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of shares being registered due to the directed share issue which was carried out in May 2020

STOCKHOLM — May 28, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announces that the company starts patient enrollment to its clinical program following the temporary recruitment pause due to the COVID-19 pandemic, announced on March 20. The program will be reinitiated at sites where local regulations and patient safety enable a restart and where recruitment, treatment and adherence to protocol, as well as safety and data monitoring are feasible

Stockholm, Sweden – 26 May 2020 – Oncopeptides AB (publ)’s (ONCO) Annual General Meeting 2020 was held today, at Tändstickspalatset in Stockholm. At the Annual General Meeting, the following principal resolutions were passed